CA2704261C - Method of synthesis of morpholino oligomers - Google Patents
Method of synthesis of morpholino oligomers Download PDFInfo
- Publication number
- CA2704261C CA2704261C CA2704261A CA2704261A CA2704261C CA 2704261 C CA2704261 C CA 2704261C CA 2704261 A CA2704261 A CA 2704261A CA 2704261 A CA2704261 A CA 2704261A CA 2704261 C CA2704261 C CA 2704261C
- Authority
- CA
- Canada
- Prior art keywords
- morpholino
- group
- protected
- compound
- ring nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2884340A CA2884340C (en) | 2007-11-15 | 2008-11-14 | Method of synthesis of morpholino oligomers |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98819207P | 2007-11-15 | 2007-11-15 | |
| US98820007P | 2007-11-15 | 2007-11-15 | |
| US60/988,192 | 2007-11-15 | ||
| US60/988,200 | 2007-11-15 | ||
| PCT/US2008/012804 WO2009064471A1 (en) | 2007-11-15 | 2008-11-14 | Method of synthesis of morpholino oligomers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2884340A Division CA2884340C (en) | 2007-11-15 | 2008-11-14 | Method of synthesis of morpholino oligomers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2704261A1 CA2704261A1 (en) | 2009-05-22 |
| CA2704261C true CA2704261C (en) | 2015-05-26 |
Family
ID=40293764
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2704261A Active CA2704261C (en) | 2007-11-15 | 2008-11-14 | Method of synthesis of morpholino oligomers |
| CA2884340A Active CA2884340C (en) | 2007-11-15 | 2008-11-14 | Method of synthesis of morpholino oligomers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2884340A Active CA2884340C (en) | 2007-11-15 | 2008-11-14 | Method of synthesis of morpholino oligomers |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2207779B1 (enExample) |
| JP (3) | JP5512533B2 (enExample) |
| KR (1) | KR101617472B1 (enExample) |
| CN (1) | CN101861318A (enExample) |
| BR (1) | BR122019021332A8 (enExample) |
| CA (2) | CA2704261C (enExample) |
| DK (1) | DK2207779T3 (enExample) |
| ES (1) | ES2479393T3 (enExample) |
| HR (1) | HRP20140646T1 (enExample) |
| IL (1) | IL205776A0 (enExample) |
| MX (1) | MX2010004955A (enExample) |
| RU (1) | RU2606627C2 (enExample) |
| WO (1) | WO2009064471A1 (enExample) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006086667A2 (en) | 2005-02-09 | 2006-08-17 | Avi Bio Pharma, Inc. | Antisense composition and method for treating muscle atrophy |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| WO2010141511A2 (en) | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
| AU2010319314C1 (en) | 2009-11-13 | 2016-09-01 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| KR101981705B1 (ko) | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| CN103154009B (zh) | 2010-09-30 | 2015-06-10 | 日本新药株式会社 | 吗啉基核酸衍生物 |
| AU2011326364B2 (en) | 2010-11-12 | 2016-08-11 | Sarepta Therapeutics, Inc. | Antisense antibacterial compounds and methods |
| AU2011367230B2 (en) | 2011-05-05 | 2017-08-10 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| CA2839593A1 (en) | 2011-07-15 | 2013-01-24 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| KR20140097398A (ko) | 2011-11-18 | 2014-08-06 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| WO2013082548A1 (en) | 2011-11-30 | 2013-06-06 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
| ES2727481T3 (es) | 2011-11-30 | 2019-10-16 | Sarepta Therapeutics Inc | Inclusión inducida de exón en atrofia muscular espinal |
| WO2013086444A2 (en) | 2011-12-08 | 2013-06-13 | Sarepta Therapeutics, Inc. | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna |
| CN108588073A (zh) | 2011-12-28 | 2018-09-28 | 日本新药株式会社 | 反义核酸 |
| US9920085B2 (en) | 2012-03-20 | 2018-03-20 | Sarepta Therapeutics, Inc. | Boronic acid conjugates of oligonucleotide analogues |
| CN102702265A (zh) * | 2012-05-14 | 2012-10-03 | 天津特安化学科技有限公司 | 一种固相合成磷酰二胺吗啉代寡核苷酸及方法 |
| WO2014113540A1 (en) | 2013-01-16 | 2014-07-24 | Iowa State University Research Foundation, Inc. | A deep intronic target for splicing correction on spinal muscular atrophy gene |
| JP6477464B2 (ja) * | 2013-05-24 | 2019-03-06 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
| AU2014317961B2 (en) | 2013-09-05 | 2020-07-30 | Murdoch University | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| EP3052512A4 (en) | 2013-09-30 | 2017-02-22 | Geron Corporation | Phosphorodiamidate backbone linkage for oligonucleotides |
| BR112016020618B1 (pt) | 2014-03-12 | 2023-04-04 | Nippon Shinyaku Co., Ltd. | Oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido |
| US9790495B2 (en) | 2014-05-16 | 2017-10-17 | Oregon State University | Antisense antibacterial compounds and methods |
| CA2948568A1 (en) | 2014-05-19 | 2015-11-26 | David Greenberg | Antisense antibacterial compounds and methods |
| PT3159409T (pt) | 2014-06-17 | 2020-01-21 | Nippon Shinyaku Co Ltd | Ácido nucleico anti-sentido para utilização no tratamento da distrofia muscular de duchenne |
| JP6673211B2 (ja) | 2014-10-14 | 2020-03-25 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
| WO2016108930A2 (en) | 2014-12-31 | 2016-07-07 | Geller Bruce L | Antisense antibacterial compounds and methods |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| KR102644053B1 (ko) | 2015-05-19 | 2024-03-06 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 펩티드 올리고뉴클레오티드 콘주게이트 |
| US10849917B2 (en) | 2015-06-01 | 2020-12-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| RS62930B1 (sr) * | 2015-08-05 | 2022-03-31 | Eisai R&D Man Co Ltd | Postupak za pripremu suštinski dijastereomerno čistog fosforodiamidatnog oligomera, fosforodiamidatni oligomer proizveden takvim postupkom i farmaceutska kompozicija koja sadrži fosforodiamidatni oligomer |
| MX2018002090A (es) | 2015-08-24 | 2018-09-12 | Halo Bio Rnai Therapeutics Inc | Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos. |
| HUE050061T2 (hu) | 2015-09-15 | 2020-12-28 | Nippon Shinyaku Co Ltd | Antiszensz nukleinsav |
| WO2017047741A1 (ja) | 2015-09-16 | 2017-03-23 | 日本新薬株式会社 | 筋萎縮症治療用アンチセンス核酸 |
| JP2018530560A (ja) | 2015-10-09 | 2018-10-18 | サレプタ セラピューティクス， インコーポレイテッド | デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法 |
| EA201891419A1 (ru) | 2015-12-15 | 2019-01-31 | Сарепта Терапьютикс, Инк. | Пептид-олигонуклеотидные конъюгаты |
| US11142764B2 (en) | 2015-12-23 | 2021-10-12 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| AU2016379399B2 (en) | 2015-12-23 | 2022-12-08 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| US11060089B2 (en) | 2016-04-18 | 2021-07-13 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| JP7042255B2 (ja) | 2016-04-29 | 2022-03-25 | サレプタ セラピューティクス， インコーポレイテッド | ヒトｌｍｎａを標的にするオリゴヌクレオチド類縁体 |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| MX384727B (es) | 2016-05-24 | 2025-03-14 | Sarepta Therapeutics Inc | Procesos para preparar oligómeros |
| TWI737736B (zh) | 2016-05-24 | 2021-09-01 | 美商薩羅塔治療公司 | 製備磷醯二胺嗎啉代寡聚物之方法 |
| MX390906B (es) | 2016-05-24 | 2025-03-21 | Sarepta Therapeutics Inc | Procesos para preparar oligómeros de morfolino fosforodiamidato. |
| US10947533B2 (en) | 2016-05-24 | 2021-03-16 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| MA45158A (fr) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Composition pharmaceutique comprenant de l'éteplirsen |
| CA3024153A1 (en) * | 2016-06-30 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| AU2017330276B2 (en) * | 2016-09-20 | 2022-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry |
| ES3051834T3 (en) | 2016-12-19 | 2025-12-30 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| NZ755416A (en) | 2016-12-19 | 2023-05-26 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| PT4122497T (pt) | 2016-12-19 | 2024-06-12 | Sarepta Therapeutics Inc | Conjugados oligoméricos de salto de exão para a distrofia muscular |
| ES2994451T3 (en) | 2017-04-20 | 2025-01-24 | Atyr Pharma Inc | Compositions for treating lung inflammation |
| EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| TWI812647B (zh) | 2017-09-25 | 2023-08-21 | 美商薩羅塔治療公司 | 經由速流合成以製備磷醯二胺嗎啉代寡聚物之製程 |
| US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
| US11560401B2 (en) | 2018-05-10 | 2023-01-24 | Nippon Shinyaku Co., Ltd. | Method for preparing oligonucleic acid compound |
| US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
| EP4219717A3 (en) | 2018-06-13 | 2023-12-20 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
| JP7345466B2 (ja) | 2018-06-26 | 2023-09-15 | 日本新薬株式会社 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
| TW202449155A (zh) | 2018-07-27 | 2024-12-16 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| BR112021011018A2 (pt) | 2018-12-13 | 2021-08-31 | Sarepta Therapeutics, Inc. | Conjugados de oligômero para exon skipping para distrofia muscular |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| WO2021025899A1 (en) | 2019-08-02 | 2021-02-11 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer pharmaceutical compositions |
| EP4059943A4 (en) | 2019-11-13 | 2024-01-31 | Nippon Shinyaku Co., Ltd. | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND |
| EP4059944A4 (en) | 2019-11-13 | 2024-04-10 | Nippon Shinyaku Co., Ltd. | METHOD FOR PREPARING AN OLIGONUCLICE ACID COMPOUND |
| EP4079329A4 (en) | 2019-12-19 | 2024-04-17 | Nippon Shinyaku Co., Ltd. | ANTISENSE NUCLEIC ACID ENABLING EXON SKIPPING |
| IL294271A (en) | 2019-12-26 | 2022-08-01 | Nippon Shinyaku Co Ltd | Antisense nucleic acid that induces skipping of exon 50 |
| PE20230237A1 (es) | 2020-02-28 | 2023-02-07 | Nippon Shinyaku Co Ltd | Acidos nucleicos antisentido que inducen la omision del exon 51 |
| EP4182315A4 (en) * | 2020-07-10 | 2024-07-03 | Changzhou Syntheall Pharmaceuticals Co., Ltd. | Processes for preparing oligonucleotides |
| EP4276104A3 (en) * | 2021-03-19 | 2024-05-22 | Bachem Holding AG | Improved oligonucleotide synthesis suppressing depurination |
| CN117279926A (zh) | 2021-04-28 | 2023-12-22 | 日本新药株式会社 | 低聚核酸化合物的制造方法 |
| WO2022239863A1 (ja) | 2021-05-13 | 2022-11-17 | 国立大学法人千葉大学 | アンチセンスオリゴマー |
| AU2022279820A1 (en) | 2021-05-28 | 2023-12-14 | Sumitomo Pharma Co., Ltd. | Antisense nucleic acid |
| JPWO2022270585A1 (enExample) | 2021-06-23 | 2022-12-29 | ||
| TW202308664A (zh) | 2021-07-08 | 2023-03-01 | 日商日本新藥股份有限公司 | 腎毒性減輕劑 |
| US20240316093A1 (en) | 2021-07-08 | 2024-09-26 | Nippon Shinyaku Co., Ltd. | Nephrotoxicity reducing agent |
| TW202317147A (zh) | 2021-07-08 | 2023-05-01 | 日商日本新藥股份有限公司 | 析出抑制劑 |
| WO2023026994A1 (ja) | 2021-08-21 | 2023-03-02 | 武田薬品工業株式会社 | ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート |
| WO2023034515A2 (en) | 2021-09-03 | 2023-03-09 | Sarepta Therapeutics, Inc. | Delivery of anitsense oligomers by mirror image peptides |
| US20240425864A1 (en) | 2021-09-30 | 2024-12-26 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
| WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| KR20240129006A (ko) | 2021-12-27 | 2024-08-27 | 니뽄 신야쿠 가부시키가이샤 | 올리고 핵산 화합물의 제조 방법 |
| KR20240155905A (ko) * | 2022-03-01 | 2024-10-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 비스-보호된 활성화된 구아닌 단량체 |
| EP4590311A2 (en) | 2022-09-21 | 2025-07-30 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
| EP4702144A1 (en) | 2023-04-27 | 2026-03-04 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of chronic kidney disease |
| JP2026526969A (ja) | 2023-08-02 | 2026-08-10 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンスオリゴマー送達のための非標準細胞透過性ペプチド |
| WO2025085810A2 (en) | 2023-10-18 | 2025-04-24 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of centronuclear myopathies |
| CN117586307B (zh) * | 2024-01-19 | 2024-04-16 | 凯莱英生命科学技术(天津)有限公司 | Pmo鸟苷单体的合成方法 |
| CN122145519A (zh) * | 2026-05-09 | 2026-06-05 | 中肽生化有限公司 | 磷酰二胺吗啉代寡核苷酸的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH577464A5 (enExample) * | 1972-09-22 | 1976-07-15 | Ciba Geigy Ag | |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| ATE312834T1 (de) * | 1989-12-20 | 2005-12-15 | Avi Biopharma Inc | Ungeladene, auf morpholin basierende polymere mit chiralen, phosphor enthaltenden brücken zwischen den untereinheiten |
| WO1991018898A1 (en) * | 1990-06-01 | 1991-12-12 | Nippon Shinyaku Co., Ltd. | Nucleic acid homolog |
| US5510476A (en) | 1994-07-07 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Carbocation scavenging during oligonucleotide synthesis |
| UA48150C2 (uk) * | 1994-11-02 | 2002-08-15 | Ай-Сі-Ен Фармасьютикалз | Похідні амінокислот або аміноспиртів, олігонуклеотид |
| US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
| LT2735568T (lt) * | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
-
2008
- 2008-11-14 MX MX2010004955A patent/MX2010004955A/es active IP Right Grant
- 2008-11-14 KR KR1020107009620A patent/KR101617472B1/ko active Active
- 2008-11-14 CA CA2704261A patent/CA2704261C/en active Active
- 2008-11-14 JP JP2010534042A patent/JP5512533B2/ja active Active
- 2008-11-14 EP EP08850132.5A patent/EP2207779B1/en active Active
- 2008-11-14 CA CA2884340A patent/CA2884340C/en active Active
- 2008-11-14 DK DK08850132.5T patent/DK2207779T3/da active
- 2008-11-14 CN CN200880116219A patent/CN101861318A/zh active Pending
- 2008-11-14 ES ES08850132.5T patent/ES2479393T3/es active Active
- 2008-11-14 WO PCT/US2008/012804 patent/WO2009064471A1/en not_active Ceased
- 2008-11-14 HR HRP20140646AT patent/HRP20140646T1/hr unknown
- 2008-11-14 RU RU2010123958A patent/RU2606627C2/ru not_active Application Discontinuation
- 2008-11-14 BR BR122019021332A patent/BR122019021332A8/pt not_active Application Discontinuation
-
2010
- 2010-05-13 IL IL205776A patent/IL205776A0/en unknown
-
2014
- 2014-03-26 JP JP2014063314A patent/JP6178744B2/ja active Active
-
2016
- 2016-06-30 JP JP2016129716A patent/JP2016196494A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0819828A8 (pt) | 2022-12-27 |
| CN101861318A (zh) | 2010-10-13 |
| RU2010123958A (ru) | 2011-12-20 |
| JP2016196494A (ja) | 2016-11-24 |
| JP2011503184A (ja) | 2011-01-27 |
| WO2009064471A1 (en) | 2009-05-22 |
| BRPI0819828A2 (pt) | 2015-05-26 |
| MX2010004955A (es) | 2010-06-30 |
| BR122019021332A2 (enExample) | 2015-05-26 |
| HK1144424A1 (en) | 2011-02-18 |
| KR101617472B1 (ko) | 2016-05-02 |
| EP2207779A1 (en) | 2010-07-21 |
| KR20100090681A (ko) | 2010-08-16 |
| CA2704261A1 (en) | 2009-05-22 |
| AU2008321409B2 (en) | 2014-08-14 |
| RU2606627C2 (ru) | 2017-01-10 |
| CA2884340C (en) | 2017-07-25 |
| BR122019021332A8 (pt) | 2022-12-06 |
| CA2884340A1 (en) | 2009-05-22 |
| DK2207779T3 (da) | 2014-07-14 |
| AU2008321409A1 (en) | 2009-05-22 |
| ES2479393T3 (es) | 2014-07-24 |
| IL205776A0 (en) | 2010-11-30 |
| HRP20140646T1 (hr) | 2014-09-26 |
| EP2207779B1 (en) | 2014-04-09 |
| JP5512533B2 (ja) | 2014-06-04 |
| JP2014159432A (ja) | 2014-09-04 |
| JP6178744B2 (ja) | 2017-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2884340C (en) | Method of synthesis of morpholino oligomers | |
| US8299206B2 (en) | Method of synthesis of morpholino oligomers | |
| US8076476B2 (en) | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits | |
| KR102504759B1 (ko) | 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법 | |
| JP2021500311A (ja) | オリゴヌクレオチド調製のための技術 | |
| AU2017269355B2 (en) | Processes for preparing oligomers | |
| JP2025521412A (ja) | 液相オリゴヌクレオチド合成のための組成物および方法 | |
| KR102523522B1 (ko) | 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법 | |
| KR102523527B1 (ko) | 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법 | |
| JP2025134950A (ja) | オリゴヌクレオチドを調製するための方法 | |
| AU2008321409B8 (en) | Method of synthesis of morpholino oligomers | |
| HK1144424B (en) | Method of synthesis of morpholino oligomers | |
| BRPI0819828B1 (pt) | Compostos de morfolino e processos para sintetizar um oligômero de morfolino | |
| HK40019008A (en) | Technologies for oligonucleotide preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD Year of fee payment: 16 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241105 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241105 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241105 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD Year of fee payment: 17 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251104 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251104 |